Company Legal Name
Latest Valuation
Founded Year
Headquarters
BillionToOne develops advanced genetic testing technology that enables prenatal screening and cancer therapy selection through blood sample analysis. Founded in 2016 and headquartered in Menlo Park, California, the company has established itself as a significant player in the precision medicine sector by offering non-invasive diagnostic solutions that provide critical genetic insights for healthcare providers and patients. The company achieved unicorn status with a $1 billion valuation, reflecting strong investor confidence in its innovative approach to genetic testing. BillionToOne continues to focus on expanding its diagnostic capabilities and advancing personalized medicine through its proprietary blood-based testing platform.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
